Literature DB >> 26758403

DNA methylation analysis in constitutional disorders: Clinical implications of the epigenome.

Laila C Schenkel1, David I Rodenhiser2,3,4, Peter J Ainsworth1,2,3,5,4, Guillaume Paré6,7, Bekim Sadikovic1,3,5,4.   

Abstract

Genomic, chromosomal, and gene-specific changes in the DNA sequence underpin both phenotypic variations in populations as well as disease associations, and the application of genomic technologies for the identification of constitutional (inherited) or somatic (acquired) alterations in DNA sequence forms a cornerstone of clinical and molecular genetics. In addition to the disruption of primary DNA sequence, the modulation of DNA function by epigenetic phenomena, in particular by DNA methylation, has long been known to play a role in the regulation of gene expression and consequent pathogenesis. However, these epigenetic factors have been identified only in a handful of pediatric conditions, including imprinting disorders. Technological advances in the past decade that have revolutionized clinical genomics are now rapidly being applied to the emerging discipline of clinical epigenomics. Here, we present an overview of epigenetic mechanisms with a focus on DNA modifications, including the molecular mechanisms of DNA methylation and subtypes of DNA modifications, and we describe the classic and emerging genomic technologies that are being applied to this study. This review focuses primarily on constitutional epigenomic conditions associated with a spectrum of developmental and intellectual disabilities. Epigenomic disorders are discussed in the context of global genomic disorders, imprinting disorders, and single gene disorders. We include a section focused on integration of genetic and epigenetic mechanisms together with their effect on clinical phenotypes. Finally, we summarize emerging epigenomic technologies and their impact on diagnostic aspects of constitutional genetic and epigenetic disorders.

Entities:  

Keywords:  Clinical genomics; DNA methylation; epigenetics; imprinting; intellectual and developmental disability

Mesh:

Year:  2016        PMID: 26758403     DOI: 10.3109/10408363.2015.1113496

Source DB:  PubMed          Journal:  Crit Rev Clin Lab Sci        ISSN: 1040-8363            Impact factor:   6.250


  12 in total

1.  The NCI-60 Methylome and Its Integration into CellMiner.

Authors:  William C Reinhold; Sudhir Varma; Margot Sunshine; Vinodh Rajapakse; Augustin Luna; Kurt W Kohn; Holly Stevenson; Yonghong Wang; Holger Heyn; Vanesa Nogales; Sebastian Moran; David J Goldstein; James H Doroshow; Paul S Meltzer; Manel Esteller; Yves Pommier
Journal:  Cancer Res       Date:  2016-12-06       Impact factor: 12.701

2.  The defining DNA methylation signature of Kabuki syndrome enables functional assessment of genetic variants of unknown clinical significance.

Authors:  Erfan Aref-Eshghi; Laila C Schenkel; Hanxin Lin; Cindy Skinner; Peter Ainsworth; Guillaume Paré; David Rodenhiser; Charles Schwartz; Bekim Sadikovic
Journal:  Epigenetics       Date:  2017-11-07       Impact factor: 4.528

3.  Clinical findings and a DNA methylation signature in kindreds with alterations in ZNF711.

Authors:  Jiyong Wang; Aidin Foroutan; Ellen Richardson; Steven A Skinner; Jack Reilly; Jennifer Kerkhof; Cynthia J Curry; Patrick S Tarpey; Stephen P Robertson; Isabelle Maystadt; Boris Keren; Joanne W Dixon; Cindy Skinner; Rachel Stapleton; Lyse Ruaud; Evren Gumus; Phillis Lakeman; Mariëlle Alders; Matthew L Tedder; Charles E Schwartz; Michael J Friez; Bekim Sadikovic; Roger E Stevenson
Journal:  Eur J Hum Genet       Date:  2022-01-07       Impact factor: 4.246

4.  The defining DNA methylation signature of Floating-Harbor Syndrome.

Authors:  Rebecca L Hood; Laila C Schenkel; Sarah M Nikkel; Peter J Ainsworth; Guillaume Pare; Kym M Boycott; Dennis E Bulman; Bekim Sadikovic
Journal:  Sci Rep       Date:  2016-12-09       Impact factor: 4.379

5.  Identification of epigenetic signature associated with alpha thalassemia/mental retardation X-linked syndrome.

Authors:  Laila C Schenkel; Kristin D Kernohan; Arran McBride; Ditta Reina; Amanda Hodge; Peter J Ainsworth; David I Rodenhiser; Guillaume Pare; Nathalie G Bérubé; Cindy Skinner; Kym M Boycott; Charles Schwartz; Bekim Sadikovic
Journal:  Epigenetics Chromatin       Date:  2017-03-10       Impact factor: 4.954

6.  DNA methylation associated with postpartum depressive symptoms overlaps findings from a genome-wide association meta-analysis of depression.

Authors:  Dana M Lapato; Roxann Roberson-Nay; Robert M Kirkpatrick; Bradley T Webb; Timothy P York; Patricia A Kinser
Journal:  Clin Epigenetics       Date:  2019-11-28       Impact factor: 6.551

7.  Identification of a methylation profile for DNMT1-associated autosomal dominant cerebellar ataxia, deafness, and narcolepsy.

Authors:  Kym M Boycott; Jodi Warman-Chardon; Bekim Sadikovic; Kristin D Kernohan; Laila Cigana Schenkel; Lijia Huang; Amanda Smith; Guillaume Pare; Peter Ainsworth
Journal:  Clin Epigenetics       Date:  2016-09-05       Impact factor: 6.551

8.  Peripheral blood epi-signature of Claes-Jensen syndrome enables sensitive and specific identification of patients and healthy carriers with pathogenic mutations in KDM5C.

Authors:  Laila C Schenkel; Erfan Aref-Eshghi; Cindy Skinner; Peter Ainsworth; Hanxin Lin; Guillaume Paré; David I Rodenhiser; Charles Schwartz; Bekim Sadikovic
Journal:  Clin Epigenetics       Date:  2018-02-14       Impact factor: 6.551

9.  Genomic DNA Methylation-Derived Algorithm Enables Accurate Detection of Malignant Prostate Tissues.

Authors:  Erfan Aref-Eshghi; Laila C Schenkel; Peter Ainsworth; Hanxin Lin; David I Rodenhiser; Jean-Claude Cutz; Bekim Sadikovic
Journal:  Front Oncol       Date:  2018-04-23       Impact factor: 6.244

10.  BAFopathies' DNA methylation epi-signatures demonstrate diagnostic utility and functional continuum of Coffin-Siris and Nicolaides-Baraitser syndromes.

Authors:  Erfan Aref-Eshghi; Eric G Bend; Rebecca L Hood; Laila C Schenkel; Deanna Alexis Carere; Rana Chakrabarti; Sandesh C S Nagamani; Sau Wai Cheung; Philippe M Campeau; Chitra Prasad; Victoria Mok Siu; Lauren Brady; Mark A Tarnopolsky; David J Callen; A Micheil Innes; Susan M White; Wendy S Meschino; Andrew Y Shuen; Guillaume Paré; Dennis E Bulman; Peter J Ainsworth; Hanxin Lin; David I Rodenhiser; Raoul C Hennekam; Kym M Boycott; Charles E Schwartz; Bekim Sadikovic
Journal:  Nat Commun       Date:  2018-11-20       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.